| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 54
| Issue : 5 | Page : 55-64 |
A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients
B Biswas1, N Ghadyalpatil2, MV Krishna3, J Deshmukh4
1 Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
2 Department of Medical Oncology, Yashoda Hospitals, Hyderabad, Telangana, India
3 Department of Medical Oncology, Apollo Cancer Institutes, Hyderabad, Telangana, India
4 Medical Affairs, AstraZeneca Pharma Limited, Bengaluru, Karnataka, India
Correspondence Address:
Dr. B Biswas
Department of Medical Oncology, Tata Medical Centre, Kolkata, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijc.IJC_589_17
The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of EGFR-mutant nonsmall cell lung cancer (NSCLC). These EGFR TKIs demonstrate a different adverse event (AE) profile as compared to conventional chemotherapy agents. They are more commonly associated with cutaneous AEs and diarrhea while hematological AEs occurred commonly with chemotherapy agents. These AEs are the extension of pharmacological effect and occur as a result of blockade of EGFR-regulated pathways in the skin and gastrointestinal tract. This review article sheds light on the safety profile of first-, second-, and third-generation EGFR TKIs based on data obtained from several clinical trials conducted in NSCLC patients and highlights trials comparing these agents with the conventional chemotherapy agents. The strategies to manage EGFR TKI-related AEs are also reviewed.
[FULL TEXT] [PDF]*
|
